ArticleJournal of controlled release : official journal of the Controlled Release Society2026
Ultrasound-guided nanocomposite hydrogel injection to enhance nerve repair via temporal delivery of a colony-stimulating factor 1 receptor inhibitor.
Article in Journal of controlled release : official journal of the Controlled Release Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Persistent or dysregulated neuroinflammation impairs regeneration following peripheral nerve injuries (PNI). Current strategies for modulating inflammation in PNI lack spatial and temporal precision, thereby limiting their regenerative efficacy. In this study, we developed a nanocomposite hydrogel (DNH/PLGA@BLZ) by combining decellularized porcine sciatic nerve hydrogel (DNH) with poly(lactic-co-glycolic acid) (PLGA) nanoparticles loaded with BLZ945, a colony-stimulating factor 1 receptor (CSF-1R) antagonist currently in clinical trials. DNH/PLGA@BLZ demonstrated excellent biocompatibility and consistent BLZ945 release, effectively suppressing CSF-1R signaling and modulating macrophage activity by promoting apoptosis and reducing migration. Ultrasound-guided, minimally invasive injections targeted the sciatic nerve and allowed in situ gelation of DNH/PLGA@BLZ pre-gel. We administered DNH/PLGA@BLZ either during surgery or at 7 days post-surgery in a mouse sciatic nerve crush model to determine the effect of the delivery time window on inflammatory modulation and subsequent nerve regeneration. In vivo results showed that early delivery during surgery, facilitated by sustained in situ release of BLZ945, suppressed early inflammation but hindered nerve regeneration. Conversely, ultrasound-guided injection of DNH/PLGA@BLZ at 7 days post-surgery, which also benefits from sustained release, modulates ongoing inflammation and effectively promotes nerve regeneration. The underlying mechanism may involve facilitating inflammation resolution and lowering inflammation levels, particularly during the middle and later stages of healing, thereby promoting nerve regeneration. In summary, this study advances the preclinical development of CSF-1R inhibitors by demonstrating that ultrasound-guided delivery enables precise, temporally adaptable administration, supporting further safety and dose-evaluation studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.